The global plasma thromboplastin antecedent market is anticipated to grow at a significant CAGR 4.9% during the forecast period (2022-2028). Plasma thromboplastin antecedent is a clotting factor whose absence is associated with a form of hemophilia coagulation factor (whose deficiency results in a hemorrhagic tendency). The major factor attributable to the market growth includes the rising prevalence of CVD, thrombosis, infectious disease, and other diseases globally. Among these, the growing global population suffering from CVD illnesses is the primary factor for the increased market growth. Globally, almost 15 million people suffer from heart attacks or similar issues, according to the World Heart Federation. In the US, one person dies from cardiovascular disease every 36 seconds. 

Heart disease claims the lives of around 659,000 people in the US each year, accounting for one out of every four mortalities. Between 2016 and 2017, the US spent $363 billion on heart disease. This covers the cost of healthcare services, medications, and lost productivity as a result of mortality. The most frequent type of heart illness, coronary heart disease killed 360,900 people in 2019. These diseases affect approximately 18.2 million persons aged 20 and up (about 6.7%). Adults under the age of 65 account for about 2 out of every 10 mortalities due to coronary artery disease. Thus, the growing application of plasma thromboplastin antecedent in such diseases is likely to spur the market growth.

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Bayer AG, and Bristol-Myers Squibb Co., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Plasma Thromboplastin Antecedent Market Report by Segment

By Type

• BAY-1213790

• BMS-262084

• EP-7041

• IONIS-FXILRx

• Others

By Application

• CVD

• Infectious Disease

• Thrombosis

• Others

Global Plasma Thromboplastin Antecedent Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa